{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:42:32Z","timestamp":1789094552867,"version":"build-2803163510"},"reference-count":155,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Depression and anxiety are the most common psychiatric disorders in end-stage renal disease (ESRD) patients treated with hemodialysis (HD) and may correlate with lower quality of life and increased mortality. Depression treatment in HD patients is still a challenge both for nephrologists and psychiatrists. The possible treatment of depressive disorders can be pharmacological and non-pharmacological. In our article, we focus on the use of sertraline, the medication which seems to be relatively safe and efficient in the abovementioned population, taking under consideration several limitations regarding the use of other selective serotonin reuptake inhibitors (SSRIs). In our paper, we discuss different aspects of sertraline use, taking into consideration possible benefits and side effects of drug administration like impact on QTc (corrected QT interval) prolongation, intradialytic hypotension (IDH), chronic kidney disease-associated pruritus (CKD-aP), bleeding, sexual functions, inflammation, or fracture risk. Before administering the medication, one should consider benefits and possible side effects, which are particularly significant in the treatment of ESRD patients; this could help to optimize clinical outcomes. Sertraline seems to be safe in the HD population when provided in proper doses. However, we still need more studies in this field since the ones performed so far were usually based on small samples and lacked placebo control.<\/jats:p>","DOI":"10.3390\/medicina57090949","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T21:36:58Z","timestamp":1631223418000},"page":"949","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Use of Sertraline in Hemodialysis Patients"],"prefix":"10.3390","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0771-6381","authenticated-orcid":false,"given":"Alicja","family":"Kubanek","sequence":"first","affiliation":[{"name":"Department of Occupational, Metabolic and Internal Diseases, Medical University of Gda\u0144sk, 81-519 Gdynia, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Przemys\u0142aw","family":"Paul","sequence":"additional","affiliation":[{"name":"Department of Occupational, Metabolic and Internal Diseases, Medical University of Gda\u0144sk, 81-519 Gdynia, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"Przybylak","sequence":"additional","affiliation":[{"name":"Department of Developmental Psychiatry, Psychotic and Geriatric Disorders, Medical University of Gdansk, 80-282 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Kanclerz","sequence":"additional","affiliation":[{"name":"Department of Occupational, Metabolic and Internal Diseases, Medical University of Gda\u0144sk, 81-519 Gdynia, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0701-1971","authenticated-orcid":false,"given":"Jakub Jan","family":"Rojek","sequence":"additional","affiliation":[{"name":"Adult Psychiatry Scientific Circle, Department of Developmental Psychiatry, Psychotic and Geriatric Disorders, Medical University of Gdansk, 80-282 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Renke","sequence":"additional","affiliation":[{"name":"Department of Occupational, Metabolic and Internal Diseases, Medical University of Gda\u0144sk, 81-519 Gdynia, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leszek","family":"Bidzan","sequence":"additional","affiliation":[{"name":"Department of Developmental Psychiatry, Psychotic and Geriatric Disorders, Medical University of Gdansk, 80-282 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0638-4565","authenticated-orcid":false,"given":"Jakub","family":"Grabowski","sequence":"additional","affiliation":[{"name":"Department of Developmental Psychiatry, Psychotic and Geriatric Disorders, Medical University of Gdansk, 80-282 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"A6","DOI":"10.1053\/j.ajkd.2019.09.003","article-title":"US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States","volume":"75","author":"Saran","year":"2020","journal-title":"Am. J. Kidney Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/ki.2013.77","article-title":"Prevalence of depression in chronic kidney disease: Systematic review and meta-analysis of observational studies","volume":"84","author":"Palmer","year":"2013","journal-title":"Kidney Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/nep.12742","article-title":"Depression in dialysis patients","volume":"21","year":"2016","journal-title":"Nephrology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1053\/j.ackd.2006.10.001","article-title":"The prevalence of symptoms in end-stage renal disease: A systematic review","volume":"14","author":"Murtagh","year":"2007","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1177\/0004867414528589","article-title":"Depression and chronic kidney disease: A review for clinicians","volume":"48","author":"Bautovich","year":"2014","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/ki.2011.358","article-title":"A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease","volume":"81","author":"Hedayati","year":"2012","journal-title":"Kidney Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1053\/j.ajkd.2019.02.017","article-title":"Anxiety symptoms, mortality and hospitalization in patients receiving maintenance dialysis: A cohort study","volume":"74","author":"Schouten","year":"2019","journal-title":"Am. J. Kidney Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.2215\/CJN.02590316","article-title":"Anxiety in Patients Treated with Hemodialysis","volume":"11","author":"Cohen","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2215\/CJN.03951106","article-title":"Screening, diagnosis and treatment of depression in patients with end-stage renal disease","volume":"2","author":"Cohen","year":"2007","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4103\/amhs.amhs_7_18","article-title":"Neuropharmacological classification of antidepressant agents based on their mechanisms of action","volume":"6","author":"Fasipe","year":"2018","journal-title":"Arch. Med. Health Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejphar.2005.01.018","article-title":"Neurochemical evaluation of the novel 5-HT1A receptor partial agonist\/serotonin reuptake inhibitor, vilazodone","volume":"510","author":"Hughes","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1590\/1516-4446-2018-0264","article-title":"Pharmacokinetics of antidepressants in patients undergoing hemodialysis: A narrative literature review","volume":"41","author":"Constantino","year":"2019","journal-title":"Braz. J. Psychiatry"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1053\/j.ajkd.2010.04.019","article-title":"Effect of daily hemodialysis on depressive symptoms and postdialysis recovery time: Interim report from the FREEDOM (Following Rehabilitation, Economics and Everyday-Dialysis Outcome Measurements) Study","volume":"56","author":"Jaber","year":"2010","journal-title":"Am J Kidney Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"key":"ref_15","unstructured":"US Food and Drug Administration (2021, September 01). FDA Drug Safety Communication: Revised Recommendations for Celexa (Citalopram Hydrobromide) Related to a Potential Risk of Abnormal Heart Rhythms with High Doses. US Food and Drug Administration (2012), Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-revised-recommendations-celexa-citalopram-hydrobromide-related."},{"key":"ref_16","unstructured":"(2021, January 03). Health Canada 2012 Health CanadaAntidepressant cipralex (Escitalopram): Updated information Regarding Dose-Related Heart Risk. Available online: http:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/hc-sc\/2012\/13674a-eng.php."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jad.2019.02.060","article-title":"Association between citalopram, escitalopram and QTc prolongation in a real-world geriatric setting","volume":"250","author":"Brown","year":"2019","journal-title":"J. Affect. Disord."},{"key":"ref_18","unstructured":"World Health Organization (1993). The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research, World Health Organization."},{"key":"ref_19","unstructured":"American Psychiatric Association (2021, September 01). DSM-5 Task Force. Diagnostic and Statistical Manual of Mental Disorders: DSM-5, Available online: https:\/\/www.ncjrs.gov\/App\/Publications\/abstract.aspx?ID=271642."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1681\/ASN.2018101032","article-title":"Comparative Cardiac Safety of Selective Serotonin Reuptake Inhibitors among Individuals receiving Maintenance Hemodialysis","volume":"30","author":"Assimon","year":"2019","journal-title":"J. Am. Soc. Nephol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cgh.2014.06.021","article-title":"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: A systematic review and meta-analysis","volume":"13","author":"Jiang","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1111\/bcp.13660","article-title":"Gastrointestinal bleeding risk of selective serotonin reuptake inhibitors by level of kidney function: A population-based cohort study","volume":"84","author":"Iwagami","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jad.2014.02.022","article-title":"Prothrombotic platelet phenotype in major depression: Downregulation by antidepressant treatment","volume":"159","author":"Navarro","year":"2014","journal-title":"J. Affect. Disord."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.thromres.2013.02.007","article-title":"Selective serotonin reuptake inhibitors reduce P2Y12 receptor-mediated amplification of platelet aggregation","volume":"131","author":"Tseng","year":"2013","journal-title":"Thromb. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1097\/SLA.0000000000000244","article-title":"The risk of perioperative bleeding in patients with chronic kidney disease: A systematic review and meta-analysis","volume":"258","author":"Acedillo","year":"2013","journal-title":"Ann. Surg."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1590\/2175-8239-jbn-2018-0189","article-title":"Effects of sertraline in the prevention of low blood pressure in patients undergoing hemodialysis","volume":"41","author":"Molin","year":"2019","journal-title":"J. Bras. Nefrol."},{"key":"ref_27","first-page":"323","article-title":"A randomized crossover clinical trial of sertraline for intradialytic hypotension","volume":"9","author":"Razeghi","year":"2015","journal-title":"Iran. J. Kidney Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000047001","article-title":"Sertraline hydrochloride treatment for patients with hemodialysis hypotension","volume":"20","author":"Yalcin","year":"2002","journal-title":"Blood Purif."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000066655","article-title":"Effect of sertraline hydrochloride on cardiac autonomic dysfunction in patients with hemodialysis-induced hypotension","volume":"93","author":"Yalcin","year":"2003","journal-title":"Nephron Physiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1440-1797.2003.00216.x","article-title":"Addition of sertraline to other therapies to reduce dialysis-associated hypotension","volume":"8","author":"Brewster","year":"2003","journal-title":"Nephrology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"363901","DOI":"10.1155\/2012\/363901","article-title":"Effect of sertraline on uremic pruritus improvement in ESRD patients","volume":"2012","author":"Shakiba","year":"2012","journal-title":"Int. J. Nephrol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1089\/jpm.2012.0504","article-title":"Use of sertraline for antihistamine-refractory uremic pruritus in renal palliative care patients","volume":"16","author":"Chan","year":"2013","journal-title":"J. Palliat. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/hdi.12540","article-title":"Sertraline can reduce uremic pruritus in hemodialysis patient: A double blind randomized clinical trial from Southern Iran","volume":"22","author":"Pakfetrat","year":"2018","journal-title":"Hemodial. Int."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.npbr.2018.10.001","article-title":"Reduction in serum IL-1\u03b2 IL-6, and IL-18 levels and Beck Depression Inventory-II score by combined sertraline and ketoprofen administration in major depressive disorder: A clinical trial","volume":"30","author":"Twayej","year":"2018","journal-title":"Neurol. Psychiatry Brain Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2007\/76396","article-title":"Pro- and anti-inflammatory cytokine balance in major depression: Effect of sertraline therapy","volume":"2007","author":"Sutcigil","year":"2007","journal-title":"Clin. Dev. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.intimp.2013.09.020","article-title":"Sertraline decreases serum level of interleukin-6 (IL-6) in hemodialysis patients with depression: Results of a randomized double-blind, placebo-controlled clinical trial","volume":"17","author":"Taraz","year":"2013","journal-title":"Int. Immunopharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.genhosppsych.2014.10.010","article-title":"Antidepressant-induced sexual dysfunction during treatment with fluoxetine, sertraline and trazodone; a randomized controlled trial","volume":"37","author":"Khazaie","year":"2015","journal-title":"Gen. Hosp. Psychiatry"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/JCP.0b013e3181a5233f","article-title":"Treatment-emergent sexual dysfunction related to antidepressants: A meta-analysis","volume":"29","author":"Serretti","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_39","first-page":"CD004541","article-title":"Antidepressants for treating depression in adults with end-stage kidney disease treated with dialysis","volume":"5","author":"Palmer","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/gps.4974","article-title":"Selective serotonin reuptake inhibitor and selective serotonin and norepinephrine reuptake inhibitor use and risk of fractures in adults: A systematic review and meta-analysis","volume":"33","author":"Khanassov","year":"2018","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00198-012-2015-9","article-title":"Relationship between use of antidepressants and risk of fractures: A meta-analysis","volume":"24","author":"Rabenda","year":"2013","journal-title":"Osteoporos. Int."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1053\/j.ajkd.2019.07.015","article-title":"Selective Serotonin Reuptake Inhibitor Use and Hip Fracture Risk Among Patients on Hemodialysis","volume":"75","author":"Vangala","year":"2020","journal-title":"Am. J. Kidney Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1093\/ndt\/gfs295","article-title":"Antidepressants for depression in stage 3\u20135 chronic kidney disease: A systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP)","volume":"27","author":"Nagler","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"826","DOI":"10.4088\/JCP.v63n0913","article-title":"Partial response and nonresponse to antidepressant therapy: Current approaches and treatment options","volume":"63","author":"Hirschfeld","year":"2002","journal-title":"J. Clin. Psychiatry."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"403","DOI":"10.4088\/JCP.v61n0602","article-title":"Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: A survey of current \u201cnext-step\u201d practices","volume":"61","author":"Fredman","year":"2000","journal-title":"J. Clin. Psychiatry"},{"key":"ref_46","unstructured":"Labbate, L.A., Fva, M., Rosenbaum, J.F., and Avana, G.W. (2010). Drugs for the treatment of depression. Handbook of Psychiatric Drug Therapy, Lippincott Williams & Wilkins. [6th ed.]."},{"key":"ref_47","first-page":"121","article-title":"Hemodialyzability of sertraline","volume":"44","author":"Schwenk","year":"1995","journal-title":"Clin. Nephrol."},{"key":"ref_48","unstructured":"Brunton, L., Chabner, B., and Knollman, B. (2010). Goodman and Gilman\u2019s The Pharmacological Basis of Therapeutics, McGraw Hill Professional. [12th ed.]."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2165\/00003088-200241150-00002","article-title":"Clinical pharmacokinetics of sertraline","volume":"41","author":"DeVane","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"959","DOI":"10.4088\/JCP.v65n0712","article-title":"Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: Patient report versus physician estimate","volume":"65","author":"Hu","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1161\/01.CIR.0000085163.21752.0A","article-title":"Sertraline AntiDepressant Heart Attack Randomized Trial Study Group. Platelet\/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: The Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy","volume":"108","author":"Serebruany","year":"2003","journal-title":"Circulation"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1503\/cmaj.100912","article-title":"Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction","volume":"183","author":"Labos","year":"2011","journal-title":"CMAJ"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"47","DOI":"10.31887\/DCNS.2007.9.1\/dhalperin","article-title":"Influence of antidepressants on hemostasis","volume":"9","author":"Halperin","year":"2007","journal-title":"Dialogues Clin. Neurosci."},{"key":"ref_54","unstructured":"Sienaert, P. (2014). Managing the Adverse Effects of Antidepressants. Psychiatr. Times, 31, Available online: https:\/\/www.psychiatrictimes.com\/view\/managing-adverse-effects-antidepressants."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/WNF.0b013e31816d1cdc","article-title":"Trazodone for the treatment of sexual dysfunction induced by serotonin reuptake inhibitors: A preliminary open-label study","volume":"32","author":"Stryjer","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"ref_56","first-page":"41","article-title":"The long-term treatment of depression","volume":"60","author":"Keller","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis","volume":"375","author":"Matsushita","year":"2010","journal-title":"Lancet"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"A7","DOI":"10.1053\/j.ajkd.2019.01.001","article-title":"US renal data system 2018 annual data report: Epidemiology of kidney disease in the United States","volume":"73","author":"Saran","year":"2019","journal-title":"Am. J. Kidney Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1038\/sj.ki.5001934","article-title":"The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease","volume":"70","author":"Charytan","year":"2006","journal-title":"Kidney Int."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1176\/appi.ajp.2013.13030325","article-title":"Comprehensive meta- analysis of excess mortality in depression in the general community versus patients with specific illnesses","volume":"171","author":"Cuijpers","year":"2014","journal-title":"Am. J. Psychiatry"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e1921043","DOI":"10.1001\/jamanetworkopen.2019.21043","article-title":"China Kadoorie Biobank Collaborative Group. Association of Depression with All-Cause and Cardiovascular Disease Mortality Among Adults in China","volume":"3","author":"Meng","year":"2020","journal-title":"JAMA Netw Open"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.4088\/JCP.13r08672","article-title":"Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation","volume":"75","author":"Beach","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.psc.2016.04.010","article-title":"Serotonin Reuptake Inhibitors and Risk of Abnormal Bleeding","volume":"39","author":"Andrade","year":"2016","journal-title":"Psychiatry Clin. N. Am."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1592\/phco.29.1.49","article-title":"Depression in patients with heart failure: Clinical implications and management","volume":"29","author":"Watson","year":"2009","journal-title":"Pharmacotherapy"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Aloisi, G., Zucchelli, A., Aloisi, B., Romanelli, G., and Marengoni, A. (2019). Depression and heart failure: An intricate relationship. Monaldi Arch. Chest Dis., 89.","DOI":"10.4081\/monaldi.2019.1029"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Post-Myocardial Infarction Depression Clinical Practice Guideline Panel (2009). AAFP guideline for the detection and management of post-myocardial infarction depression. Ann. Fam. Med., 7, 71\u201379.","DOI":"10.1370\/afm.918"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.pcad.2015.11.003","article-title":"Treatment of Depression in Patients with Concomitant Cardiac Disease","volume":"58","author":"Teply","year":"2016","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1176\/appi.ajp.2013.12060860","article-title":"Drug-induced long QT in adult psychiatric inpatients: The 5-year cross sectional ECG Screening Outcome in Psychiatry study","volume":"170","author":"Girardin","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"f288","DOI":"10.1136\/bmj.f288","article-title":"QT interval and antidepressant use: A cross sectional study of electronic health records","volume":"346","author":"Castro","year":"2013","journal-title":"BMJ"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1055\/s-2004-835678","article-title":"Platelet dysfunction in renal failure","volume":"30","author":"Boccardo","year":"2004","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1681\/ASN.2015050535","article-title":"The Risk of Major Hemorrhage with CKD","volume":"27","author":"Molnar","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.amjcard.2015.11.029","article-title":"Differences in whole blood platelet aggregation at baseline and in response to aspirin and aspirin plus Clopidogrel in patients with versus without chronic kidney disease","volume":"117","author":"Jain","year":"2016","journal-title":"Am. J. Cardiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00004714-200004000-00004","article-title":"Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment","volume":"20","author":"Pollock","year":"2000","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Jain, N., Wan, F., Kothari, M., Adelodun, A., Ware, J., Sarode, R., and Hedayati, S.S. (2019). Association of platelet function with depression and its treatment with sertraline in patients with chronic kidney disease: Analysis of a randomized trial. BMC Nephrol., 20.","DOI":"10.1186\/s12882-019-1576-7"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/hdi.12138","article-title":"Intradialytic hypotension: Frequency, sources of variation and correlation with clinical outcome","volume":"18","author":"Sands","year":"2014","journal-title":"Hemodial. Int."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1681\/ASN.2007091006","article-title":"Recent advances in the prevention and management of intradialytic hypotension","volume":"19","author":"Palmer","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_77","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients","volume":"45","author":"Diseases","year":"2005","journal-title":"Am. J. Kidney Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1681\/ASN.2014020222","article-title":"Association of mortality risk with various definitions of intradialytic hypotension","volume":"26","author":"Flythe","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/sdi.12627","article-title":"A brief review of intradialytic hypotension with a focus on survival","volume":"30","author":"Chou","year":"2017","journal-title":"Semin. Dial."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/j.1523-1755.2004.00812.x","article-title":"Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients","volume":"66","author":"Shoji","year":"2004","journal-title":"Kidney Int."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2215\/CJN.03900808","article-title":"Hemodialysis-induced cardiac injury: Determinants and associated outcomes","volume":"4","author":"Burton","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1038\/sj.ki.5001975","article-title":"Pathogenesis and treatment of dialysis hypotension","volume":"70","author":"Sulowicz","year":"2006","journal-title":"Kidney Int."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/0735-1097(94)90308-5","article-title":"Use of sertraline hydrochloride in the treatment of refractory neurocardiogenic syncope in children and adolescents","volume":"24","author":"Grubb","year":"1994","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_84","first-page":"445","article-title":"Prevention of intradialytic hypotensive episodes: Is setraline an effective pharmacological approach?","volume":"41","author":"Georgianos","year":"2019","journal-title":"J. Bras. Nefrol. \u2019orgao Of. Soc. Bras. Lat.-Am. Nefrologia"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.ekir.2020.04.027","article-title":"CKD-Associated Pruritus: New Insights Into Diagnosis, Pathogenesis, and Management","volume":"5","author":"Verduzco","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2340\/00015555-2280","article-title":"Clinical Findings and Provision of Care in Haemodialysis Patients with Chronic Itch: New Results from the German Epidemiological Haemodialysis Itch Study","volume":"96","author":"Hayani","year":"2016","journal-title":"Acta Derm. Venereol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1093\/ndt\/gfl461","article-title":"Pruritus in haemodialysis patients: International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"21","author":"Pisoni","year":"2006","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.2215\/CJN.03280317","article-title":"International Comparisons of Prevalence, Awareness, and Treatment of Pruritus in People on Hemodialysis","volume":"12","author":"Rayner","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.2215\/CJN.00100110","article-title":"ITCH National Registry Investigators. A longitudinal study of uremic pruritus in hemodialysis patients","volume":"5","author":"Mathur","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1053\/j.ajkd.2016.07.031","article-title":"Sleep Disorders, Restless Legs Syndrome, and Uremic Pruritus: Diagnosis and Treatment of Common Symptoms in Dialysis Patients","volume":"69","author":"Scherer","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e00964","DOI":"10.1002\/brb3.964","article-title":"The behavioral study on the interactive aggravation between pruritus and depression","volume":"8","author":"Wang","year":"2018","journal-title":"Brain Behav."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2340\/00015555-3164","article-title":"European S2k Guideline on Chronic Pruritus","volume":"99","author":"Weisshaar","year":"2019","journal-title":"Acta Derm. Venereol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jaad.2017.08.025","article-title":"Use of oral antidepressants in patients with chronic pruritus: A systematic review","volume":"77","author":"Kouwenhoven","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.jpainsymman.2003.05.004","article-title":"Paroxetine in the treatment of severe non-dermatological pruritus: A randomized, controlled trial","volume":"26","author":"Zylicz","year":"2003","journal-title":"J. Pain Symptom Manag."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0885-3924(02)00645-0","article-title":"Mirtazapine for pruritus","volume":"25","author":"Davis","year":"2003","journal-title":"J. Pain Symptom Manag."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s11255-020-02473-3","article-title":"Effect of mirtazapine on pruritus in patients on hemodialysis: A cross-over pilot study","volume":"52","author":"Gholyaf","year":"2020","journal-title":"Int. Urol. Nephrol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/hep.21553","article-title":"Sertraline as a first-line treatment for cholestatic pruritus","volume":"45","author":"Mayo","year":"2007","journal-title":"Hepatology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/ijd.14708","article-title":"Gabapentin for uremic pruritus: A systematic review of randomized controlled trials","volume":"59","author":"Castillo","year":"2020","journal-title":"Int. J. Dermatol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1912770","article-title":"KALM-1 Trial Investigators. A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus","volume":"382","author":"Fishbane","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/ndt\/gfk092","article-title":"The effect of single and repeatedly high concentrations of C-reactive protein on cardiovascular and non-cardiovascular mortality in patients starting with dialysis","volume":"21","author":"Boeschoten","year":"2006","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000085525","article-title":"Inflammation in End-Stage Renal Disease\u2014A Fire that Burns within","volume":"149","author":"Stenvinkel","year":"2005","journal-title":"Cardiovasc. Disord. Hemodial."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1046\/j.1523-1755.1999.00273.x","article-title":"Inflammation enhances cardiovascular risk and mortality in hemodialysis patients","volume":"55","author":"Zimmermann","year":"1999","journal-title":"Kidney Int."},{"key":"ref_103","first-page":"S16","article-title":"Epidemiology of cardiovascular disease in chronic renal disease","volume":"9","author":"Foley","year":"1998","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_104","first-page":"1","article-title":"Biomarkery uszkodzenia naczy\u0144 u pacjent\u00f3w z przewlek\u0142\u0105 chorob\u0105 nerek","volume":"10","author":"Krata","year":"2017","journal-title":"Forum Nefrol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10157-015-1211-2","article-title":"Hepatocyte growth factor (HGF) and hemodialysis: Physiopathology and clinical implications","volume":"20","author":"Libetta","year":"2016","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/ki.1994.117","article-title":"Plasma levels of IL-1\u03b2, TNF\u03b1 and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients","volume":"45","author":"Pereira","year":"1994","journal-title":"Kidney Int."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1111\/tri.12636","article-title":"Evaluation of biomarkers of cell cycle arrest and inflammation in prediction of dialysis or recovery after kidney transplantation","volume":"28","author":"Pianta","year":"2015","journal-title":"Transpl. Int."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/hdi.12200","article-title":"Association between depression and inflammatory\/anti-inflammatory cytokines in chronic kidney disease and end-stage renal disease patients: A review of literature","volume":"19","author":"Taraz","year":"2015","journal-title":"Hemodial. Int."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11011-008-9118-1","article-title":"The inflammatory & neurodegenerative (I&ND) hypothesis of depression: Leads for future research and new drug developments in depression","volume":"24","author":"Maes","year":"2009","journal-title":"Metab. Brain Dis."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s11011-012-9323-9","article-title":"IL-1\u03b2, IL-6, IL-8, IL-10, IFN-\u03b3, TNF-\u03b1 and its relationship with lipid parameters in patients with major depression","volume":"27","author":"Hocaoglu","year":"2012","journal-title":"Metab. Brain Dis."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/npr2.12100","article-title":"Serum level of soluble interleukin 6 receptor is a useful biomarker for identification of treatment-resistant major depressive disorder","volume":"40","author":"Yamasaki","year":"2020","journal-title":"Neuropsychopharmacol. Rep."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1176\/appi.focus.10.4.413","article-title":"The Inflammatory Hypothesis of Depression","volume":"10","author":"Soskin","year":"2012","journal-title":"FOCUS"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.286.23.2947","article-title":"Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: A randomized trial","volume":"286","author":"Kroenke","year":"2001","journal-title":"J. Am. Med. Assoc."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/YIC.0000000000000023","article-title":"A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?","volume":"29","author":"Sanchez","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/jama.288.6.701","article-title":"Sertraline treatment of major depression in patients with acute MI or unstable angina","volume":"288","author":"Glassman","year":"2002","journal-title":"J. Am. Med. Assoc."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2010.03.068","article-title":"Safety and efficacy of sertraline for depression in patients with heart failure: Results of the SADHART-CHF (Sertraline against depression and heart disease in chronic heart failure) trial","volume":"56","author":"Jiang","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1053\/j.ajkd.2013.08.024","article-title":"Association between depression and mortality in patients receiving long-term dialysis: A systematic review and meta-analysis","volume":"63","author":"Farrokhi","year":"2014","journal-title":"Am. J. Kidney Dis."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2215\/CJN.02120216","article-title":"Sertraline versus placebo in patients with major depressive disorder undergoing hemodialysis: A randomized, controlled feasibility trial","volume":"12","author":"Friedli","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1001\/jama.2017.17131","article-title":"Effect of sertraline on depressive symptoms in patients with chronic kidney disease without dialysis dependence: The CAST randomized clinical trial","volume":"318","author":"Hedayati","year":"2017","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.cct.2010.06.005","article-title":"Methodology of a randomized clinical trial of symptom management strategies in patients receiving chronic hemodialysis: The SMILE study","volume":"31","author":"Weisbord","year":"2010","journal-title":"Contemp. Clin. Trials"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2215\/CJN.04450512","article-title":"Comparison of symptom management strategies for pain, erectile dysfunction, and depression in patients receiving chronic hemodialysis: A cluster randomized effectiveness trial","volume":"8","author":"Weisbord","year":"2013","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2215\/CJN.05470513","article-title":"Sexual function, activity, and satisfaction among women receiving maintenance hemodialysis","volume":"9","author":"Mor","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/00926239708403923","article-title":"SSRI-induced sexual dysfunction: Fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients","volume":"23","author":"Liorca","year":"1997","journal-title":"J. Sex Marital. Ther."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1053\/j.ajkd.2010.06.016","article-title":"Prevalence and correlates of self-reported sexual dysfunction in CKD: A meta-analysis of observational studies","volume":"56","author":"Navaneethan","year":"2010","journal-title":"Am. J. Kidney Dis."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.ackd.2007.01.002","article-title":"Sexual Function in Chronic Kidney Disease","volume":"14","author":"Anantharaman","year":"2007","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11154-016-9385-9","article-title":"Gonadal dysfunction in chronic kidney disease","volume":"18","author":"Palmer","year":"2017","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1681\/ASN.V1061381","article-title":"Sexual Dysfunction in Uremia","volume":"10","author":"Palmer","year":"1999","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41443-020-0295-8","article-title":"Prevalence of erectile dysfunction in patients with chronic kidney disease: A systematic review and meta-analysis","volume":"33","author":"Pizzol","year":"2020","journal-title":"Int. J. Impot. Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1111\/j.1743-6109.2012.02709.x","article-title":"Bidirectional association between depression and sexual dysfunction: A systematic review and meta-analysis","volume":"9","author":"Atlantis","year":"2012","journal-title":"J. Sex. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/JCP.0b013e31819c76e9","article-title":"Sexual dysfunction, depression, and the impact of antidepressants","volume":"29","author":"Kennedy","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1542-4758.2011.00585.x","article-title":"Sexual functioning in chronic kidney disease: The association with depression and anxiety","volume":"16","author":"Theofilou","year":"2012","journal-title":"Hemodial. Int."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1111\/jsm.12980","article-title":"Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction","volume":"12","author":"Jacobsen","year":"2015","journal-title":"J. Sex. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1177\/0269881109351966","article-title":"Reversal of SSRI-induced female sexual dysfunction by adjunctive bupropion in menstruating women: A double-blind, placebo-controlled and randomized study","volume":"25","author":"Safarinejad","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000447034","article-title":"The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature","volume":"85","author":"Carvalho","year":"2016","journal-title":"Psychother Psychosom."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"191","DOI":"10.9740\/mhc.2016.07.191","article-title":"Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: A narrative literature review","volume":"6","author":"Jing","year":"2016","journal-title":"Ment. Health Clin."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/2045125317720642","article-title":"Assessment and management of sexual dysfunction in the context of depression","volume":"8","author":"Chokka","year":"2018","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1177\/1060028014550645","article-title":"Risk of QT\/QTc Prolongation Among Newer Non-SSRI Antidepressants","volume":"48","author":"Jasiak","year":"2014","journal-title":"Ann. Pharmacother."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.2215\/CJN.10901012","article-title":"Temporal trends in the incidence, treatment, and outcomes of hip fracture in older patients initiating dialysis in the United States","volume":"8","author":"Nair","year":"2013","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1053\/j.ajkd.2013.02.368","article-title":"Trends in hip fracture rates in US hemodialysis patients, 1993-2010","volume":"62","author":"Arneson","year":"2013","journal-title":"Am. J. Kidney Dis."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s11255-016-1388-7","article-title":"The effect of hemodialysis on balance measurements and risk of fall","volume":"48","author":"Erken","year":"2016","journal-title":"Int. Urol. Nephrol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1053\/j.ajkd.2004.09.027","article-title":"Falls in hemodialysis patients: Prospective study of incidence, risk factors, and complications","volume":"45","author":"Desmet","year":"2005","journal-title":"Am. J. Kidney Dis."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1002\/gps.4770","article-title":"Does baseline depression increase the risk of unexplained and accidental falls in a cohort of community-dwelling older people? Data from The Irish Longitudinal Study on Ageing (TILDA)","volume":"33","author":"Briggs","year":"2018","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.archger.2012.12.006","article-title":"Risk factors for falls in older people in nursing homes and hospitals. A systematic review and meta-analysis","volume":"56","author":"Deandrea","year":"2013","journal-title":"Arch. Gerontol. Geriatr."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/ajag.12628","article-title":"The relationship between discharge medications and falls in post-hospitalised older adults: A 6-month follow-up","volume":"38","author":"Lam","year":"2019","journal-title":"Australas. J. Ageing"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1017\/S104161021700103X","article-title":"Understanding temporal relationships between depression, falls, and physical activity in a cohort of post-hospitalized older adults\u2014A breakthrough or a conundrum?","volume":"29","author":"Lee","year":"2017","journal-title":"Int. Psychogeriatr."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1365-2850.2010.01686.x","article-title":"Falls in older adult psychiatric patients: Equipping nurses with knowledge to make a difference","volume":"18","author":"Stubbs","year":"2011","journal-title":"J. Psychiatr. Ment. Health Nurs."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Kistler, B.M., Khubchandani, J., Bennett, P., Wilund, K.R., and Sosnoff, J. (2020). Depressive Disorders Are Associated with Risk of Falls in People with Chronic Kidney Disease. J. Am. Psychiatr. Nurses Assoc., Epub ahead of print.","DOI":"10.1177\/1078390320970648"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s11255-019-02148-8","article-title":"Epidemiology of falls and fall-related injuries among middle-aged adults with kidney disease","volume":"51","author":"Kistler","year":"2019","journal-title":"Int. Urol. Nephrol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"E82","DOI":"10.5888\/pcd15.170518","article-title":"Falls and Fall-Related Injuries Among US Adults Aged 65 or Older with Chronic Kidney Disease","volume":"15","author":"Kistler","year":"2018","journal-title":"Prev. Chronic Dis."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/ki.2013.147","article-title":"Prevention and treatment of protein energy wasting in chronic kidney disease patients: A consensus statement by the International Society of Renal Nutrition and Metabolism","volume":"84","author":"Ikizler","year":"2013","journal-title":"Kidney Int."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1053\/j.jrn.2018.08.006","article-title":"Global Prevalence of Protein-Energy Wasting in Kidney Disease: A Meta-analysis of Contemporary Observational Studies from the International Society of Renal Nutrition and Metabolism","volume":"28","author":"Carrero","year":"2018","journal-title":"J. Ren. Nutr."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Soto, P.J., De Giorgi, A., Senno, E., Tiseo, R., Ferraresi, A., Canella, C., Rodr\u00edguez-Borrego, M.A., Manfredini, R., and Fabbian, F. (2015). Renal disease and accidental falls: A review of published evidence. BMC Nephrol., 16.","DOI":"10.1186\/s12882-015-0173-7"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.2215\/CJN.09500916","article-title":"Fractures in Patients with CKD: Time for Action","volume":"11","author":"Moe","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/jbmr.485","article-title":"The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat","volume":"26","author":"Moe","year":"2011","journal-title":"J. Bone Miner Res."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40266-015-0323-4","article-title":"Effects of Depression and Serotonergic Antidepressants on Bone: Mechanisms and Implications for the Treatment of Depression","volume":"33","author":"Fernandes","year":"2016","journal-title":"Drugs Aging"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/9\/949\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:59:30Z","timestamp":1760165970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/9\/949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,9]]},"references-count":155,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["medicina57090949"],"URL":"https:\/\/doi.org\/10.3390\/medicina57090949","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,9]]}}}